New hope for CML patients: asciminib trial targets treatment failures

NCT ID NCT06629584

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests asciminib, a daily pill, in 40 adults with chronic myeloid leukemia whose first treatment with a TKI drug didn't work or caused side effects. Participants take asciminib for up to 2 years. The main goal is to see how many achieve a major molecular response by 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: asciminib
What this could lead to: If successful, asciminib could offer a new second-line option for people with chronic myeloid leukemia who did not respond to or couldn't tolerate their first treatment.
What could go wrong: This is a small, early-phase study with only 40 participants. It may not show enough benefit or could have side effects that limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC PHASE CHRONIC MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer chronic myelogenous leukemia, BCR-ABL1 positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT SOLID TUMORS

Contacts and locations

Locations

The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.